Genetic markers linked to restlessness from antidepressants in young people
Studies genes linked to restlessness from SSRI antidepressants in youth with depression or anxiety.
Plain-language title generated from the registry record
Registry title: Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
Key facts
- Where
- Winnipeg, CanadaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 24 years old?
Source: NCT06763081, who can take part
Where in Canada
- Shared Health FacilitiesWinnipeg, CanadaTaking people
- University of Manitoba College of PharmacyWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Manitoba
- Trial code
- NCT06763081
- Record updated
- 8 September 2025
- Original description
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.Read full original descriptionShow less
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Inclusion: Resident of Manitoba; Age, 6 - 24 years; Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD); Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram [Celexa], Escitalopram [Cipralex], Fluoxetine [Prozac], Fluvoxamine [Luvox], Sertraline [Zoloft], Paroxetine [Paxil/Plaxil CR]) therapy; [Cases Only] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug; [Controls Only] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks.
Exclusion: Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder; History of liver or bone marrow (hematopoietic cell) transplant; Inability of parent/legal guardian/mature minors to give informed consent; Inability of the child (6 - 13 years) to give informed assent; Unwillingness of the child to provide a saliva sample for genetic analysis.